Modified QLB with Liposomal Bupivacaine Delivers Superior Post-Cesarean Analgesia, Reducing Opioid Use

Inadequate post-cesarean analgesia remains a significant clinical challenge, leading to increased opioid consumption, higher risks of chronic pain, and postpartum depression. Current standards, like the transversus abdominis plane (TAP) block, offer limited efficacy, while the more effective anterior quadratus lumborum block (QLB III) often requires complex patient repositioning and can cause undesirable quadriceps numbness. This study addresses these limitations by developing and evaluating a modified QLB technique designed for enhanced efficacy and safety.

This single-center, randomized, single-blind trial enrolled 70 patients undergoing elective cesarean delivery. Participants were randomized to either the modified QLB group (Group Q) or the TAP block group (Group T). The intervention involved the modified QLB combined with liposomal bupivacaine (specific dose not detailed in abstract), while the control received a standard TAP block. The primary outcome measured was the postoperative Day 1 VAS pain score. Secondary outcomes included VAS scores on Days 2 and 3, pain during uterine compression and oxytocin infusion, opioid consumption, recovery metrics, and adverse events.

Baseline characteristics were well balanced between the two groups (all p>0.05). The modified QLB group demonstrated significantly lower VAS pain scores at rest, during uterine palpation, and during oxytocin infusion throughout the first three postoperative days (all p<0.001). This superior pain control translated into fewer patient-controlled analgesia (PCIA) demands and a notable reduction in morphine-equivalent consumption in the modified QLB group. Recovery indicators, such as time to ambulation and discharge, were comparable between groups, with no significant differences in overall adverse event rates. Importantly, the study reported no severe neurological or local complications in either cohort, underscoring the favorable safety profile of the modified QLB.

The modified QLB group achieved significantly lower VAS pain scores across all measured time points and activities (all p<0.001), alongside reduced opioid consumption.